| Lifesource Of North Carolina | |
|
5530 Northrop Rd Milton FL 32570-8701 | |
| (910) 742-9243 | |
| Not Available |
| Full Name | Lifesource Of North Carolina |
|---|---|
| Speciality | Psychologist |
| Location | 5530 Northrop Rd, Milton, Florida |
| Authorized Official Name and Position | Peggy Baddour (PRESIDENT) |
| Authorized Official Contact | 9107779165 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Lifesource Of North Carolina Po Box 538622 Atlanta GA 30353-8622 Ph: (910) 794-4521 | Lifesource Of North Carolina 5530 Northrop Rd Milton FL 32570-8701 Ph: (910) 742-9243 |
| NPI Number | 1730648288 |
|---|---|
| Provider Enumeration Date | 03/14/2019 |
| Last Update Date | 03/25/2021 |
| Certification Date | 03/25/2021 |
| Medicare PECOS PAC ID | 7416132428 |
|---|---|
| Medicare Enrollment ID | O20190327002120 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730648288 | NPI | - | NPPES |
| Provider Name | Maureen D Kapatkin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740381458 PECOS PAC ID: 4385706506 Enrollment ID: I20081223000312 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Shirley J Tabor |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780922500 PECOS PAC ID: 5193979441 Enrollment ID: I20130214000074 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Merri Schiff |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1154747137 PECOS PAC ID: 9335461268 Enrollment ID: I20141204000854 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Hassan Ayaz Bokhari |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1811158082 PECOS PAC ID: 2062653462 Enrollment ID: I20150721002094 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Barbara Joan Rubin |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1669801551 PECOS PAC ID: 7911241179 Enrollment ID: I20190401000642 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Marilyn Christine Madden |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902923055 PECOS PAC ID: 8325134562 Enrollment ID: I20190703000627 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Willie James Campbell |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1417217092 PECOS PAC ID: 1456500545 Enrollment ID: I20200414000690 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Shakila Moore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1891339099 PECOS PAC ID: 8820429434 Enrollment ID: I20200515000618 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Jana Erika Cua |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1225491087 PECOS PAC ID: 6608160635 Enrollment ID: I20200615001481 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Emmanuella Armand |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447863345 PECOS PAC ID: 6406267095 Enrollment ID: I20201203001475 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Salim Elhalaby |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750658662 PECOS PAC ID: 9436414067 Enrollment ID: I20210702000694 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Terraseeta Craig |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366908287 PECOS PAC ID: 9739574021 Enrollment ID: I20220705003146 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Paige Marenah |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1942650791 PECOS PAC ID: 6608114574 Enrollment ID: I20221203000401 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Kayla Lane |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023701307 PECOS PAC ID: 9931569357 Enrollment ID: I20231004000850 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Audrea Maurine Moore |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1124161153 PECOS PAC ID: 8325496144 Enrollment ID: I20231204002907 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
| Provider Name | Shannon Pereira |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245849645 PECOS PAC ID: 6406241579 Enrollment ID: I20231215000268 |
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
News Archive
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Researchers at UT Southwestern Medical Center at Dallas have utilized an animal model to trace how the virus that causes AIDS in humans may enter and spread throughout the body following an oral exposure.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).
IPF is a rare and fatal lung disease that causes permanent scarring of the lungs, leading to debilitating shortness of breath and cough in affected patients. It affects as many as 132,000 Americans, most commonly those over the age of 65.
› Verified 3 days ago
Santa Rosa County School Board Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6751 Berryhill St, Milton, FL 32570 Phone: 850-983-5151 Fax: 850-983-5577 | |
My Therapy Partner, Inc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 6196 Clear Creek Road, Milton, FL 32570 Phone: 866-441-6002 | |
Spectrum House Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6479 Caroline St, Milton, FL 32570 Phone: 850-607-6910 | |
Behavior Quest Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4891 Glover Ln, Milton, FL 32570 Phone: 850-626-0606 Fax: 850-361-3443 | |
Lifelong Behavioral Services, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4629 Church St, Milton, FL 32583 Phone: 850-503-6636 Fax: 850-626-6132 | |
Emerald Coast City Of Hope, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3220 Avalon Blvd, Milton, FL 32583 Phone: 850-910-3926 | |
Suds Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4519 Woodbine Rd, Milton, FL 32571 Phone: 850-778-3747 Fax: 850-807-5147 |